These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

99 related items for PubMed ID: 2394774

  • 21. CV 205-502 treatment of hyperprolactinemia.
    Vance ML, Cragun JR, Reimnitz C, Chang RJ, Rashef E, Blackwell RE, Miller MM, Molitch ME.
    J Clin Endocrinol Metab; 1989 Feb; 68(2):336-9. PubMed ID: 2521863
    [Abstract] [Full Text] [Related]

  • 22. Treatment of macroprolactinomas with a new non-ergot, long-acting dopaminergic drug, CV 205-502.
    van't Verlaat JW, Croughs RJ, Brownell J.
    Clin Endocrinol (Oxf); 1990 Nov; 33(5):619-24. PubMed ID: 1979262
    [Abstract] [Full Text] [Related]

  • 23. Efficacy of quinagolide in resistance to dopamine agonists: results of a multicenter study. Club de l'Hypophyse.
    Rohmer V, Freneau E, Morange I, Simonetta C.
    Ann Endocrinol (Paris); 2000 Nov; 61(5):411-7. PubMed ID: 11084391
    [Abstract] [Full Text] [Related]

  • 24. Lower prolactin levels during cabergoline treatment are associated to tumor shrinkage in prolactin secreting pituitary adenoma.
    Lombardi M, Lupi I, Cosottini M, Rossi G, Manetti L, Raffaelli V, Sardella C, Martino E, Bogazzi F.
    Horm Metab Res; 2014 Dec; 46(13):939-42. PubMed ID: 25230324
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma.
    Cannavò S, Curtò L, Squadrito S, Almoto B, Vieni A, Trimarchi F.
    J Endocrinol Invest; 1999 May; 22(5):354-9. PubMed ID: 10401709
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Cabergoline: long-acting oral treatment of hyperprolactinemic disorders.
    Ferrari C, Mattei A, Melis GB, Paracchi A, Muratori M, Faglia G, Sghedoni D, Crosignani PG.
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1201-6. PubMed ID: 2656736
    [Abstract] [Full Text] [Related]

  • 34. Primary medical therapy of micro- and macroprolactinomas in men.
    Pinzone JJ, Katznelson L, Danila DC, Pauler DK, Miller CS, Klibanski A.
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3053-7. PubMed ID: 10999785
    [Abstract] [Full Text] [Related]

  • 35. Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up.
    Colao A, Loche S, Cappa M, Di Sarno A, Landi ML, Sarnacchiaro F, Facciolli G, Lombardi G.
    J Clin Endocrinol Metab; 1998 Aug; 83(8):2777-80. PubMed ID: 9709946
    [Abstract] [Full Text] [Related]

  • 36. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients.
    Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R, Volpe R, Di Salle F, Cirillo S, Annunziato L, Lombardi G.
    J Clin Endocrinol Metab; 2000 Jun; 85(6):2247-52. PubMed ID: 10852458
    [Abstract] [Full Text] [Related]

  • 37. Pergolide for the treatment of pituitary tumors secreting prolactin or growth hormone.
    Kleinberg DL, Boyd AE, Wardlaw S, Frantz AG, George A, Bryan N, Hilal S, Greising J, Hamilton D, Seltzer T, Sommers CJ.
    N Engl J Med; 1983 Sep 22; 309(12):704-9. PubMed ID: 6888442
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.